Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Plos One|March 4, 2016
Uncertainty of Monetary Valued Ecosystem Services - Value Transfer Functions for Global MappingStefan Schmidt, Ameur M Manceur, Ralf SeppeltCrohn'S & Colitis 360|September 6, 2023
Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United StatesMaryia Zhdanava, Ruizhi Zhao, Ameur M Manceur, et al.BMC Health Services Research|February 20, 2020
The societal economic burden of autosomal dominant polycystic kidney disease in the United StatesMartin Cloutier, Ameur M Manceur, Annie Guerin, et al.Current Medical Research and Opinion|August 15, 2018
Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysisDominic Pilon, Tony B Amos, Rhiannon Kamstra, et al.Crohn'S & Colitis 360|February 13, 2023
Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional AgentsDominic Pilon, Zhijie Ding, Erik Muser, et al.Clinical Therapeutics|July 13, 2023
Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic AgentMaryia Zhdanava, Sumesh Kachroo, Ameur M Manceur, et al.Current Medical Research and Opinion|May 18, 2021
Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclaxKerry A Rogers, Bruno Emond, Ameur M Manceur, et al.Current Medical Research and Opinion|August 11, 2023
Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumabMaryia Zhdanava, Zhijie Ding, Ameur M Manceur, et al.Journal of Managed Care & Specialty Pharmacy|July 31, 2023
Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumabMaryia Zhdanava, Ruizhi Zhao, Ameur M Manceur, et al.Current Medical Research and Opinion|January 10, 2020
Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trialAmeur M Manceur, Mike Durkin, Akshay Kharat, et al.Pageof 4